Strategic Alliance between Facet Life Sciences and XCancer
Facet Life Sciences, renowned for its expertise in regulatory strategy and drug development services, has forged an alliance with XCancer, a leader in theranostic clinical research. This partnership aims to enhance the development and approval processes for innovative radiopharmaceutical therapies in oncology.
Enhancing Clinical Trial Visibility
As part of this collaboration, Facet Life Sciences is now highlighted on TheranosticTrials.Org, a cutting-edge platform created by XCancer. This platform is designed to connect researchers, clinicians, and sponsors to foster collaboration, share expertise, and promote cancer innovation accessibility.
Streamlined Development Pathways
The alliance merges Facet’s extensive regulatory and development knowledge with XCancer’s vast clinical trial network, paving the way for sponsors to bring precision diagnostic and therapeutic radiopharmaceuticals to patients more efficiently. By harnessing these combined strengths, the organizations are poised to tackle the complexities of the oncology landscape.
Expert Insights
Dr. Lisa Jenkins VanLuvanee, the COO of Facet Life Sciences, expressed enthusiasm for the partnership, stating, "Our mission focuses on expediting patient access to diagnostic and radiopharmaceutical therapies. Collaborating with XCancer allows us to leverage their groundbreaking clinical capabilities alongside our regulatory expertise. Our mutual goal is to advance theranostic therapies and enhance patient access to innovative treatments."
Innovative Cancer Care Solutions
Dr. Luke Nordquist, CEO of XCancer and founder of TheranosticTrials.Org, shared his vision for the partnership: "Our combined efforts are creating an ecosystem that eliminates barriers for sponsors, accelerates clinical trial activations, and ultimately provides life-changing radiopharmaceutical therapies to patients in urgent need. This partnership embodies the essence of theranostics — merging diagnostics with therapeutics to deliver personalized cancer care."
Contributions to Oncology
This collaboration represents a significant stride towards simplifying the intricate development and regulatory processes often associated with novel therapies. By eliminating delays in these critical pathways, the Facet and XCancer partnership aims to ensure that patients gain quicker access to potentially life-saving innovations.
About Facet Life Sciences
Facet Life Sciences is a dedicated employee-owned firm that aids life sciences organizations through every development phase. With proficiency across regulatory strategies, drug development planning, and U.S. regulatory submissions, Facet enables sponsors to adeptly navigate complex requirements and deliver innovative radiopharmaceutical solutions to patients. Their emphasis remains strong on diagnostic and theranostic pharmaceuticals, oncology, and rare disease programs.
About XCancer
XCancer, founding its operations in Omaha, Nebraska, is recognized globally for its oncology clinical research and theranostic innovation. Established by Dr. Luke Nordquist, the organization manages one of the country’s largest community-based research networks. This network conducts numerous Phase I–III clinical trials, encompassing over 20 pioneering studies in radiopharmaceuticals, and ongoing exploration in precision oncology.
About Theranostic Trials
TheranosticTrials.Org was created with the mission of advancing cooperation, awareness, access, and education in Theranostics. This platform, developed by Dr. Luke Nordquist, serves as a vital resource connecting researchers, clinicians, sponsors, and patients, thus promoting clinical trial visibility and increasing access to radiopharmaceutical innovations. By fostering strategic partnerships, TheranosticTrials.Org accelerates the growth of the theranostic ecosystem, ensuring more patients receive essential cancer treatments.
Frequently Asked Questions
What is the purpose of the Facet and XCancer partnership?
The partnership aims to accelerate the development and approval of innovative radiopharmaceutical therapies in oncology.
How will this collaboration benefit patients?
By streamlining the development and regulatory processes, the collaboration will enhance patient access to cutting-edge cancer treatments.
Who are key leaders in this partnership?
Dr. Lisa Jenkins VanLuvanee from Facet Life Sciences and Dr. Luke Nordquist from XCancer are leading this strategic alliance.
What kind of research does XCancer conduct?
XCancer conducts a vast array of oncology clinical trials, including many first-in-world studies focusing on radiopharmaceuticals.
What is TheranosticTrials.Org?
TheranosticTrials.Org is a platform designed to enhance collaboration and visibility in theranostics, aiming to expand access to personalized cancer care.
